Dangerous Synthetic Drug Control Act of 2016

Bill: 114-hr-5934
Sponsor: full_name: Rep. Katko, John [R-NY-24]
Introduced: 2016-09-06
Policy area: Crime and Law Enforcement
Latest action: action_date: 2016-09-15
text: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

Summaries:
action_date: 2016-09-06
action_desc: Introduced in House
text: <p><b>Dangerous Synthetic Drug Control Act of 2016</b></p> <p>This bill amends the Controlled Substances Act to add certain synthetic opioids, hallucinogens, and cannabinoids to schedule I. (A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)</p>

tv_txt: I 114th CONGRESS 2d Session H. R. 5934 IN THE HOUSE OF REPRESENTATIVES September 6, 2016 Mr. Katko (for himself, Mr. Cicilline , and Mr. Dent ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Controlled Substances Act to add certain synthetic substances to schedule I, and for other purposes.

1. Short title This Act may be cited as the Dangerous Synthetic Drug Control Act of 2016 . 2. Treatment of certain designer drugs as schedule I controlled substances (a) Cannabimimetic agents Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (d)(2)(B)— (1) in clause (xiv) by striking and at the end; (2) in clause (xv) by striking the period and inserting a semicolon; and (3) by adding at the end the following: (xvi) 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–251); (xvii) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (4′-methyl JWH–073); (xviii) 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–302); (xix) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F–APICA); (xx) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F–PB–22); (xxi) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA); (xxii) N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (MN–24); (xxiii) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ–2201); (xxiv) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADBICA); (xxv) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F–AMB); and (xxvi) methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (MA–CHMINACA). . (b) Synthetic opioids Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (a) by adding at the end the following: (43) Butyryl fentanyl. (44) beta-Hydroxythiofentanyl. (45) Acetyl fentanyl. . (c) Other drugs Schedule I, as set forth in section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), is amended in subsection (c) by adding at the end the following: (29) 1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one (α-naphyrone). (30) 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine (5–APDB). (31) 1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine (6–APDB). (32) 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI). (33) 5-iodo-2,3-dihydro-1H-inden-2-amine (5–IAI). (34) 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine (bromo-dragonfly). (35) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine (DOC). (36) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine (MEM). .